In re Niaspan Antitrust Litigation
On December 23, 2013, Berger Montague was appointed co-lead counsel in this class action challenging a pay for delay deal concerning the brand name drug Niaspan (extended release niacin). On September 8, 2014, the Honorable Jan E. DuBois denied defendants’ motion to dismiss. Discovery has closed and class certification briefing has completed.
Lead Attorneys: David F. Sorensen, Andrew Curley, Nick Urban